A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)
Latest Information Update: 24 Apr 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VIALE-T
- Sponsors AbbVie; AbbVie Germany
Most Recent Events
- 03 Jan 2025 Planned End Date changed from 1 Jan 2028 to 1 Nov 2026.
- 03 Jan 2025 Planned primary completion date changed from 1 Jan 2028 to 1 Apr 2025.
- 19 Dec 2024 Planned End Date changed from 30 Nov 2026 to 1 Jan 2028.